Quick Overview: Circular RNA is edging toward a modality breakout - and Circio Holding ASA is one of the few players with early pharma ... If off-the-shelf CAR-T works, the economics of oncology will be rewritten - and Allogene Therapeutics is arguably closest to that ... Kyverna Therapeutics is emerging as one of the most closely watched players in autoimmune cell therapy. Their CD19 CAR-T ...
Jefferies Healthcare Conference 2025 Onyx - Detailed Overview & Context
Circular RNA is edging toward a modality breakout - and Circio Holding ASA is one of the few players with early pharma ... If off-the-shelf CAR-T works, the economics of oncology will be rewritten - and Allogene Therapeutics is arguably closest to that ... Kyverna Therapeutics is emerging as one of the most closely watched players in autoimmune cell therapy. Their CD19 CAR-T ... Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ... Our 10th edition of brought together the thinkers and builders shaping the future of therapeutics — from frontier ... Lexicon Pharmaceuticals are pioneers of drugs targeting heart failure, HOCM and neuropathic pain. Their obesity drug, LX9851, ...
Primary hyperoxaluria type 1 – PH1 – pushes more than 70% of patients into end-stage kidney disease, often before they finish ... Nxera (Jefferies Global Healthcare Conference) The EMA has approved more than 25 advanced therapy medicinal products since the ATMP regulation came into force in 2007, ... Brandi Roberts, CFO of Definium Therapeutics, discusses upcoming trial readouts at the 2026 RBC Capital Markets Global ... What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks? For a condition like retinitis ... Leader Jeffries at the 2026 CAP IDEAS Conference
On this episode of Stock Movers: - Concentrix (CNXC) shares fall as the software company's second-quarter forecast was weaker ...
